BI
PRTK

BVF Inc’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BVF Inc’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-575,000
Closed -$8M – 34
2016
Q2 		$8M Buy
+575,000
New +$8.47M 1.7% 18
2014
Q4 		– Sell
-12,500
Closed -$304K – 38
2014
Q3 		$304K Hold
12,500
– – 0.06% 32
2014
Q2 		$299K Hold
12,500
– – 0.05% 29
2014
Q1 		$462K Hold
12,500
– – 0.07% 28
2013
Q4 		$504K Hold
12,500
– – 0.09% 24
2013
Q3 		$477K Hold
12,500
– – 0.08% 26
2013
Q2 		$453K Buy
+12,500
New +$536K 0.09% 23

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BVF Inc's PRTK Position: Q3 2016 in Review

BVF Inc sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2016, closing a stake of 575,000 shares — an estimated $8M sold.

BVF Inc first reported a position in PRTK in Q2 2013 and held it in 7 quarters. The position peaked at $8M in Q2 2016. 86 funds tracked by Wall St. Rank hold PRTK as of Q3 2016.

  • BVF Inc reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • BVF Inc sold 575,000 Paratek Pharmaceuticals, Inc. shares in Q3 2016, an estimated $8M.
  • BVF Inc first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 7 quarters.
  • BVF Inc's Paratek Pharmaceuticals, Inc. position peaked at $8M in Q2 2016.
  • 86 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2016.

Based on BVF Inc's 13F filing for Q3 2016, filed 14 Nov 2016.